• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 466195 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414747958 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414747958 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Buyers Accumulating Shares of Acadia Pharmaceuticals on 3.0x Above-Average Volume (ACAD)

Published on Mon, 03/25/2013 - 13:09
By Robert Cotter

Shares of Acadia Pharmaceuticals are trading today in above average volume, with the share price rising 9.4% to $8.28. About 5.9 million shares have been traded today, as compared to the 30-day average volume of 1.9 million shares. Unusually high volume can signify a potential turning point or validate a breakout.

There is potential upside of 1.4% for shares of Acadia Pharmaceuticals based on a current price of $8.28 and an average consensus analyst price target of $8.40. The stock should find initial support at its 50-day moving average (MA) of $6.14 and further support at its 200-day MA of $3.42.

In the past 52 weeks, shares of Acadia Pharmaceuticals have traded between a low of $1.29 and a high of $8.81 and are now at $8.28, which is 542% above that low price. The 200-day and 50-day moving averages have moved 4.33% higher and 3.64% higher over the past week, respectively.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

Take-Two Interactive Software Looks to C...

Shares of Take-Two Interactive Software (NASDAQ:TTWO) traded at a new 52-week high toda ...

Shares of Talisman Energy Fall Below Pre...

Shares of Talisman Energy (NYSE:TLM) traded at a new 52-week low today of $6.12. Appro ...

Recent 52-Week High Exceeded in Shares o...

Shares of Hanover Insurance (NYSE:THG) traded at a new 52-week high today of $66.88. T ...

Recent 52-Week Low Surpassed in Shares o...

Shares of Taseko Mines (AMEX:TGB) traded at a new 52-week low today of $1.35. This new ...

Transglobe Energy Looks to Continue to T...

Shares of Transglobe Energy (NASDAQ:TGA) traded today at $4.35, breaking its 52-week lo ...

Shares of TFS Financial Rise Above Previ...

Shares of TFS Financial (NASDAQ:TFSL) traded today at $15.09, breaking its 52-week high ...

Watch for Continued Gains in Shares of T...

Teva Pharmaceutical Industries (NASDAQ:TEVA) traded at a new 52-week high today of $55. ...

Shares of Integrys Energy Rise to a New ...

Integrys Energy (NYSE:TEG) traded at a new 52-week high today of $72.23. So far today ...